3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
2
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
2
apalutamide
2
abiraterone
2
Testosterone
2
Radiosurgery
2
Leuprolide
2
Golytely
2
Exercise
2
Cryotherapy
2
Abiraterone Acetate
2
zanubrutinib
1
venetoclax
1
stenoparib
1
relugolix
1
olaparib
1
nilutamide
1
leucoselect phytosome
1
ibrutinib
1
histrelin
1
enzalutamide
1
copanlisib
1
capivasertib
1
bicalutamide
1
avelumab
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
acalabrutinib
1
Waiting Lists
1
Triptorelin Pamoate
1
Temozolomide
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
FED
×
Ethiodized Oil
×
1 year
×
Clear all
NCT05842174
2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2
Recruiting
93 enrolled